Novel therapies for pancreatic adenocarcinoma

Current Gastroenterology Reports

Volumn 6, Issue 2, 2004, Pages 119-125

  Pino, Simona M ^a   Xiong, Henry Q ^a   McConkey, David ^a   Abbruzzese, James L ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BEVACIZUMAB; BORTEZOMIB; CELECOXIB; CETUXIMAB; CYCLOOXYGENASE 2 INHIBITOR; ENDOSTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FUMAGILLOL CHLOROACETYLCARBAMATE; GEMCITABINE; IMMUNOGLOBULIN G ANTIBODY; LONAFARNIB; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; PELITINIB; PROTEASOME INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; ROFECOXIB; SUNITINIB; TANOMASTAT; TIPIFARNIB; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB; VATALANIB; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; COMPLEMENTARY RNA; CYSTEINE PROTEINASE; DEOXYCYTIDINE; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR; HYDROXAMIC ACID; MATRIX METALLOPROTEINASE; METALLOPROTEINASE; MULTIENZYME COMPLEX; PROTEASOME; PROTEIN TYROSINE KINASE;

ACNE; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER SURVIVAL; CELL LEVEL; CLINICAL TRIAL; DIARRHEA; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; GENE THERAPY; HUMAN; LIVER DYSFUNCTION; NONHUMAN; PANCREAS ADENOCARCINOMA; REVIEW; SYMPTOMATOLOGY; ADENOCARCINOMA; DRUG ANTAGONISM; GENETICS; PANCREAS TUMOR; VASCULARIZATION;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYSTEINE ENDOPEPTIDASES; DEOXYCYTIDINE; EPIDERMAL GROWTH FACTOR; HUMANS; HYDROXAMIC ACIDS; MATRIX METALLOPROTEINASES; METALLOENDOPEPTIDASES; MULTIENZYME COMPLEXES; PANCREATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN-TYROSINE KINASES; RNA, ANTISENSE;

EID: 3042628477     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-004-0038-x     Document Type: Review

References (50)

1. Jemal A, Murray T, Samuels A: Cancer statistics, 2003. CA Cancer J Clin 2003, 53(Suppl 1):5-26.
2. Neoptolemos JP, Dunn JA, Stocken DD, et al.: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomized controlled trial. Lancet 2001, 358:1576-1585.
3. Abrams RA, Lillemoe KD, Plantadosi S: Continuing controversy over adjuvant therapy of pancreatic cancer. Lancet 2001, 358:1565-1566.
4. Burris HA, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403-2413.
5. Von Hoff D, Mahadevan D, Bearss D: New developments in the treatment of patients with pancreatic cancer. Clin Oncol Updates 2001, 4:1-15.
6. Lohr M, Trautmann B, Gottler M, et al.: Human ductal adenocarcinomas of the pancreas express extracellular matrix proteins. Br J Cancer 1994, 69:144-151.
7. Sato H, Takino T, Okada Y, et al.: A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 1994, 370:61-65.
8. Bramhall SR, Rosemurgy A, Brown PD, et al.: Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001, 19:3447-3455.
9. Bramhall SR, Schulz J, Nemunaitis J, et al.: A double-blind placebo-controlled, randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002, 87(Suppl 2):61-167.
10. Moore MJ, Hamm J, Dancey J, et al.: Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 129566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003, 21:3296-3302.
11. Hess KR, Abbruzzese JL: Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design. J Clin Oncol 2001, 19:3445-3446.
12. Hruban RH, Van Mansfeld AD, Offerhaus GJ, et al.: K-ras oncogene activation in adenocarcinoma of the human pancreas: a study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993, 143:545-554.
13. Adjei AA: Blocking oncogenic ras signalling for cancer therapy. J Natl Cancer Inst 2001, 93:1062-1074.
14. Casey PJ, Solski PA, Der CJ, et al.: p21ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci U S A 1989, 86:8323-8327.
15. Lersch C, Van Cutsem E, Amado R, et al.: Randomized phase II study of SCH 66336 and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas [abstract]. Proc ASCO 2001, 20:608.
16. Macdonald JS, Chansky K, Whitehead R, et al.: A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest Oncology Group (SWOG) [abstract]. Proc ASCO 2002, 21:548.
17. Cohen SJ, Ho L, Ranganathan S, et al.: Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol 2003, 21:1301-1306.
18. Van Cutsem E, Karasek P, Oettle H, et al.: Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer (PC) [abstract]. Proc ASCO 2002, 21:517.
19. Arteaga CL: Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 2002, 29:3-9.
20. Funatomi H, Itakura J, Ishiwata T, et al.: Amphiregulin antisense oligonucleotide inhibits growth of T3M4 human pancreatic cancer cells and sensitizes the cells to EGF receptor-targeted therapy. Int J Cancer 1997, 72:512-517.
21. Sato JD, Kawamoto T, Le AD, et al.: Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1983, 1:511-529.
22. Mendelsohn J: BIockade of receptors for growth factors: an anticancer therapy: the fourth annual Joseph H. Burchenal American Association for Cancer Research Clinical Research Award Lecture. Clin Cancer Res 2000, 6:747-753.
23. Bruns CJ, Harbison MT, Davis DW, et al.: Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000, 6:1936-1948.
24. Bruns CJ, Solorzano CC, Harbison MT, et al.: Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000, 60:2926-2935.
25. Abbruzzese J, Rosenberg A, Xiong Q, et al.: Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer [abstract]. Proc ASCO 2001, 20:518.
26. Safran H, Ramanathan RK, Schwartz J, et al.: Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER2/neu [abstract]. Proc ASCO 2001, 20:517.
27. Greenberger LM, Discafani C, Wang YF, et al.: EKB-569: a new irreversible inhibitor of epidermal growth factor receptor tyrosine kinase for the treatment of cancer [abstract]. Clin Cancer Res 2000, 6:4544s.
28. Morgan JA, Bukowski RM, Xiong H, et al.: Preliminary report of a phase 1 study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR), given in combination with gemcitabine to patients with advanced pancreatic cancer [abstract]. Proc ASCO 2003, 22:788.
29. Molina MA, Sitja-Arnau M, Lemoine MG, et al.: Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999, 59:4356-4362.
30. Yip-Schneider MT, Barnard DS, Billings SD, et al.: Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 2000, 21:139-146.
31. Yip-Schneider MT, Sweeney CJ, Jung SH, et al.: Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther 2001, 298:976-985.
32. Yip-Schneider MT, Wiesenauer CA, Schmidt CM: Inhibition of the phosphatidylinositol 3′-kinase signaling pathway increases the responsiveness of pancreatic carcinoma cells to sulindac. J Gastrointest Surg 2003, 7:354-363.
33. Masferrer JL, Leahy KM, Koki AT, et al.: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000, 60:1306-1311.
34. Leahy KM, Ornberg RL, Wang Y, et al.: Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002, 62:625-631.
35. Xiong HQ, Du M, Wolff RA, et al.: Parmacology study of celecoxib in combination with gemcitabine for advanced pancreatic cancer [abstract]. Proc ASCO 2002, 21:448.
36. Smith SE, Burris HA, Loehrer PJ, et al.: Preliminary report of a phase II trial of gemcitabine combined with celecoxib for advanced pancreatic cancer [abstract]. Proc ASCO 2003, 22:1502.
37. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
38. Koong AC, Mehta VK, Le QT, et al.: Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 2000, 48:919-922.
39. Kindler HL, Ansari R, Lester E, et al.: Bevacizumab (B) plus gemcitabine (G) in patients (pts) with advanced pancreatic cancer (PC) [abstract]. Proc ASCO 2003, 22:1037.
40. Chen F, Castranova V, Shi X: New insights into the role of nuclear factor B in cell growth regulation. Am J Pathol 2001, 159:387-397.
41. Wang W, Abbruzzese JL, Evans DB, et al.: The nuclear factor B ReIA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999, 59:119-127.
42. Ryan DP, Elder JP, Winkelmann J, et al.: Pharmacokinetic and pharmacodynamic phase 1 study of PS-341 and gemcitabine in patients with advanced solid tumors [abstract]. Proc ASCO 2002, 21:379.
43. Goeze JP, Nielsen FC, Burcharth F, et al.: Closing the gastrin loop in pancreatic carcinoma: coexpression of gastrin and its receptor in solid human pancreatic adenocarcinoma. Cancer 2000, 88:2487-2494.
44. Watson SA, Michaeli D, Grimes S, et al.: Gastrimmune raises antibodies that neutralize amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer. Cancer Res 1996, 56:880-885.
45. Gilliam AD, Henwood M, Watson SA, et al.: G17DT therapy may improve the survival of patients with advanced pancreatic carcinoma [abstract]. Proc ASCO 2001, 20:533.
46. Crooke ST: Proof of mechanism of antisense drugs. Antisense Nucleic Acid Drug Dev 1996, 6:145-147.
47. Monia BP, Johnston DJ, Ecker DJ, et al.: Selective inhibition of mutant H-ras MRNA expression by antisense oligonucleotides. J Biol Chem 1992, 267:19954-19962.
48. Chen G, Oh S, Monia BP, et al.: Antisense oligonucleotides demonstrate a dominant role of c-Ki-ras proteins in regulating the proliferation of diploid human fibroblasts. J Biol Chem 1996, 271:28259-28265.
49. Burch PA, Alberts SR, Schroeder MT, et al.: Gemcitabine and ISIS-2504 for patients with pancreatic adenocarcinoma (ACA): A North Central Cancer Treatment Group (NCCTG) phase II study [abstract]. Proc ASCO 2003, 22:1038.
50. Hecht JR, Bedford R, Abbruzzese JL, et al.: A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 2003, 9:555-561.